Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease

Status Active, not recruiting

Clinical Trial Summary

This is a phase 2 open-label trial designed to evaluate the efficacy of tildrakizumab in improving graft-versus-host disease (GVHD)-free relapse-free survival after myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancy.

Clinical Trial Description

Study Rationale: GVHD remains a major cause of morbidity and mortality following myeloablative conditioning (MAC) alloHCT. Proinflammatory cytokines play a central role in initiation and development of acute GVHD and as such, inhibition of these cytokines has been examined for both prevention and treatment of GVHD. Interleukin (IL)-23 is a proinflammatory cytokine which the investigators' lab has shown to have a unique and selective role in induction of colonic inflammation during acute GVHD and that this cytokine serves as a critical mediator linking conditioning regimen-induced mucosal injury and endotoxin lipopolysaccharide (LPS) translocation to subsequent proinflammatory cytokine production and GVHD-associated pathological damage. Moreover, additional studies have demonstrated that blocking the IL-23 signaling pathway has not abrogated the graft-versus-tumor effect. Tildrakizumab is a commercially available anti-IL-23 antibody FDA approved for the treatment of moderate to severe psoriasis with good tolerance. The investigators hypothesize that blocking IL-23, with tildrakizumab, will reduce GVHD rates for patients undergoing MAC alloHCT without having an impact on relapse rates, thus improving GVHD-free relapse-free survival (GRFS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04112810
Study type	Interventional
Source	Medical College of Wisconsin
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 1, 2020
Completion date	June 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05433090` - An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies	N/A
Completed	`NCT00061620` - Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies	Phase 1
Enrolling by invitation	`NCT02473757` - Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Not yet recruiting	`NCT06296368` - DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics	N/A
Recruiting	`NCT02032446` - Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease	Phase 1/Phase 2
Recruiting	`NCT01203722` - Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies	Phase 1/Phase 2
Recruiting	`NCT02884375` - Elderly CAncer Patient	N/A
Completed	`NCT00780052` - Infusional C-myb ASODN in Advanced Hematologic Malignancies	Phase 1
Recruiting	`NCT04098393` - Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation	Phase 1
Recruiting	`NCT06028828` - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT04538599` - RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies	Phase 1
Completed	`NCT03609827` - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT01380756` - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia	Phase 1
Recruiting	`NCT05849207` - Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant	Phase 1
Not yet recruiting	`NCT05028478` - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies	Phase 1/Phase 2
Active, not recruiting	`NCT02494258` - A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders	Phase 2
Completed	`NCT03212560` - Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
Active, not recruiting	`NCT02600208` - Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device	Phase 2/Phase 3
Completed	`NCT02145403` - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	Phase 1/Phase 2
Completed	`NCT01949545` - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment	Phase 1